The federal Project Grant award R43DK137616 for $275,766.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds Biosurfaces Inc., a for-profit medical device company, to develop and evaluate an implantable, electrospun cell chamber device loaded with human pancreatic islets. The device aims to provide an immune-protected environment to support long-term growth and function of insulin-producing beta cells, without requiring immunosuppressive drugs. Key milestones include demonstrating the device's efficacy to restore insulin independence in a diabetic rat model for at least 60 days, as well as evidence of biocompatibility and healthy tissue integration. Successful completion of this Phase I Small Business Innovation Research (SBIR) project will enable Biosurfaces to advance the device to more comprehensive biocompatibility and efficacy studies in a porcine model, and eventually human clinical trials, as a potential new treatment option for type 1 diabetes patients.
Generated 7/16/24, 6:48 AM